Remove 2027 Remove Drugs Remove Trials
article thumbnail

How Many Clinical Trials Are Run by CROs?

Vial

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. That is, how many clinical trials are actually managed by these organizations?

article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

This ability to activate pathways could be possible for almost all proteins, however the biggest differentiation was to consider areas that were hard to drug – transcription factors, ion channels, intracellular proteins, etc. Is it more important to have a clinical meaningful drug candidate OR convenience?

RNA 67
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Biotech Startup Contraction Continues… And That’s A Good Thing

LifeSciVC

While it may help shake out some incremental advances for the therapeutic armamentarium, this dynamic also clearly creates inefficiencies and waste – both in terms of capital deployment, but also for patients’ engagement and clinical trial activity. Fewer startups over time should ameliorate this crowding dynamic to some extent.

DNA 131
article thumbnail

Wearables, Sensors, and Apps Part 1 – Updates on FDA’s PDUFA VII Goals for the Use of Digital Health Technologies in Drug and Biological Product Development

FDA Law Blog: Biosimilars

DHTs have been used in clinical trials for decades in the context of measurements made when participants visit clinical trial sites. FDA has made good progress on these initial goals, providing updates on the first four on the Digital Health Technologies (DHTs) for Drug Development website.

article thumbnail

AI-Designed Drugs vs. Traditional Drug Discovery: Pros and Cons

Vial

In the ever-evolving field of medical science, artificial intelligence (AI) has emerged as a revolutionary tool, particularly in drug discovery. As a newer alternative to the time-consuming nature of traditional candidate screening and drug discovery, AI-designed drugs have started to make their mark, promising quick and efficient results.

Drugs 52
article thumbnail

Article EMA Thank You Updated EUDAMED roadmap projects mandatory use of some processes as early as December 2025

Agency IQ

Ultimately, this module will interact with CTIS , the drug clinical trial information system. The independent auditing schedule showed publication of full functionality in mid-2027. Another notable challenge has been development of the clinical investigation and performance study module (CI/PS).

article thumbnail

Q BioMed’s Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer

The Pharma Data

Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. billion by 2027. NEW YORK , Jan. Q BioMed Inc.

FDA 40